A gene signature-based approach identifies thioridazine as an inhibitor of phosphatidylinositol-3′-kinase (PI3K)/AKT pathway in ovarian cancer cells

Gynecologic Oncology

Volumn 120, Issue 1, 2011, Pages 121-127

  Rho, Seung Bae ^a   Kim, Boh Ram ^a   Kang, Sokbom ^a  

^a National Cancer Center   (South Korea)

Author keywords

Chemical screening; Ovarian cancer; Phosphatidylinositol 3 kinase; Thioridazine

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CISPLATIN; CP 690334 01; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; FLUPHENAZINE; GELDANAMYCIN; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROCHLORPERAZINE; PROTEIN P16; PROTEIN P21; RAPAMYCIN; TANESPIMYCIN; THIORIDAZINE; TRICHOSTATIN A; TRIFLUOPERAZINE; UNCLASSIFIED DRUG; VORINOSTAT; WORTMANNIN;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL VIABILITY; COMPUTER PROGRAM; CONTROLLED STUDY; CYTOTOXICITY; ENZYME INHIBITION; GENETIC SCREENING; HUMAN; HUMAN CELL; IMMUNOBLOTTING; OVARY CANCER; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CISPLATIN; FEMALE; G0 PHASE; G1 PHASE; GENE EXPRESSION PROFILING; HUMANS; OVARIAN NEOPLASMS; PACLITAXEL; PHOSPHATIDYLINOSITOL 3-KINASE; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; THIORIDAZINE;

EID: 78649905860     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.10.003     Document Type: Article

References (45)

1. A. Jemal, T. Murray, E. Ward, A. Samuels, R.C. Tiwari, and A. Ghafoor Cancer statistics, 2005 CA Cancer J Clin 55 2005 10 30
2. K.K. Shih, and D.S. Chi Maximal cytoreductive effort in epithelial ovarian cancer surgery J Gynecol Oncol 21 2010 75 80
3. T.F. Franke, C.P. Hornik, L. Segev, G.A. Shostak, and C. Sugimoto PI3K/Akt and apoptosis: size matters Oncogene 22 2003 8983 8998
4. L.C. Cantley, and B.G. Neel New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway Proc Natl Acad Sci USA 96 1999 4240 4245
5. X. Yang, M. Fraser, U.M. Moll, A. Basak, and B.K. Tsang Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway Cancer Res 66 2006 3126 3136
6. D.A. Altomare, H.Q. Wang, K.L. Skele, A. De Rienzo, A.J. Klein-Szanto, and A.K. Godwin AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth Oncogene 23 2004 5853 5857
7. T.F. Franke, D.R. Kaplan, L.C. Cantley, and A. Toker Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3, 4-bisphosphate Science 275 1997 665 668
8. B. Vanhaesebroeck, and M.D. Waterfield Signaling by distinct classes of phosphoinositide 3-kinases Exp Cell Res 253 1999 239 254
9. Y. Wang, A. Helland, R. Holm, G.B. Kristensen, and A.L. Borresen-Dale PIK3CA mutations in advanced ovarian carcinomas Hum Mutat 25 2005 322
10. L. Shayesteh, Y. Lu, W.L. Kuo, R. Baldocchi, T. Godfrey, and C. Collins PIK3CA is implicated as an oncogene in ovarian cancer Nat Genet 21 1999 99 102
11. D.A. Levine, F. Bogomolniy, C.J. Yee, A. Lash, R.R. Barakat, and P.I. Borgen Frequent mutation of the PIK3CA gene in ovarian and breast cancers Clin Cancer Res 11 2005 2875 2878
12. I.G. Campbell, S.E. Russell, and W.A. Phillips PIK3CA mutations in ovarian cancer Clin Cancer Res 11 2005 7042 author reply 7042-3
13. J. Woenckhaus, K. Steger, K. Sturm, K. Munstedt, F.E. Franke, and I. Fenic Prognostic value of PIK3CA and phosphorylated AKT expression in ovarian cancer Virchows Arch 450 2007 387 395
14. I.K. Kolasa, A. Rembiszewska, A. Felisiak, I. Ziolkowska-Seta, M. Murawska, and J. Moes PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients Cancer Biol Ther 8 2009 21 26
15. J. Cowap, and J. Hardy Thioridazine in the management of cancer-related sweating J Pain Symptom Manage 15 1998 266
16. D.S. Zhukovsky Fever and sweats in the patient with advanced cancer Hematol Oncol Clin North Am 16 2002 579 588 viii
17. K.L. Ly, J. Chidgey, J. Addington-Hall, and M. Hotopf Depression in palliative care: a systematic review: Part 2. Treatment Palliat Med 16 2002 279 284
18. A. Ramu, R. Spanier, H. Rahamimoff, and Z. Fuks Restoration of doxorubicin responsiveness in doxorubicin-resistant P388 murine leukaemia cells Br J Cancer 50 1984 501 507 (Pubitemid 14015592)
19. S. Akiyama, N. Shiraishi, Y. Kuratomi, M. Nakagawa, and M. Kuwano Circumvention of multiple-drug resistance in human cancer cells by thioridazine, trifluoperazine, and chlorpromazine J Natl Cancer Inst 76 1986 839 844
20. W.H. Munyon, R. Salo, and D.F. Briones Cytotoxic effects of neuroleptic drugs Psychopharmacology (Berl) 91 1987 182 188
21. J.S. Strobl, K.L. Kirkwood, T.K. Lantz, M.A. Lewine, V.A. Peterson, and J.F. Worley 3rd Inhibition of human breast cancer cell proliferation in tissue culture by the neuroleptic agents pimozide and thioridazine Cancer Res 50 1990 5399 5405
22. L. Glass-Marmor, H. Morgenstern, and R. Beitner Calmodulin antagonists decrease glucose 1, 6-bisphosphate, fructose 1, 6-bisphosphate, ATP and viability of melanoma cells Eur J Pharmacol 313 1996 265 271
23. A.A. Pantazaki, and T.S. Lialiaris A combined biochemical and cytogenetic study of thioridazine-induced damage to nucleic acids Mutagenesis 14 1999 243 248
24. M. Kamiwatari, Y. Nagata, H. Kikuchi, A. Yoshimura, T. Sumizawa, and N. Shudo Correlation between reversing of multidrug resistance and inhibiting of [3H]azidopine photolabeling of P-glycoprotein by newly synthesized dihydropyridine analogues in a human cell line Cancer Res 49 1989 3190 3195
25. T. Rodrigues, A.C. Santos, A.A. Pigoso, F.E. Mingatto, S.A. Uyemura, and C. Curti Thioridazine interacts with the membrane of mitochondria acquiring antioxidant activity toward apoptosis-potentially implicated mechanisms Br J Pharmacol 136 2002 136 142
26. A. Basta-Kaim, B. Budziszewska, G. Jagla, W. Nowak, M. Kubera, and W. Lason Inhibitory effect of antipsychotic drugs on the Con A- and LPS-induced proliferative activity of mouse splenocytes: a possible mechanism of action J Physiol Pharmacol 57 2006 247 264
27. I. Gil-Ad, B. Shtaif, Y. Levkovitz, M. Dayag, E. Zeldich, and A. Weizman Characterization of phenothiazine-induced apoptosis in neuroblastoma and glioma cell lines: clinical relevance and possible application for brain-derived tumors J Mol Neurosci 22 2004 189 198
28. I. Gil-Ad, B. Shtaif, Y. Levkovitz, J. Nordenberg, M. Taler, and I. Korov Phenothiazines induce apoptosis in a B16 mouse melanoma cell line and attenuate in vivo melanoma tumor growth Oncol Rep 15 2006 107 112
29. J. Lamb, E.D. Crawford, D. Peck, J.W. Modell, I.C. Blat, and M.J. Wrobel The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease Science 313 2006 1929 1935
30. J. Lamb The Connectivity Map: a new tool for biomedical research Nat Rev Cancer 7 2007 54 60
31. D.A. Fruman, F. Mauvais-Jarvis, D.A. Pollard, C.M. Yballe, D. Brazil, and R.T. Bronson Hypoglycaemia, liver necrosis and perinatal death in mice lacking all isoforms of phosphoinositide 3-kinase p85 alpha Nat Genet 26 2000 379 382
32. L. Hu, J. Hofmann, and R.B. Jaffe Phosphatidylinositol 3-kinase mediates angiogenesis and vascular permeability associated with ovarian carcinoma Clin Cancer Res 11 2005 8208 8212
33. L. Hu, C. Zaloudek, G.B. Mills, J. Gray, and R.B. Jaffe In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002) Clin Cancer Res 6 2000 880 886
34. S. Mabuchi, D.A. Altomare, M. Cheung, L. Zhang, P.I. Poulikakos, and H.H. Hensley RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model Clin Cancer Res 13 2007 4261 4270
35. S. Mabuchi, C. Kawase, D.A. Altomare, K. Morishige, K. Sawada, and M. Hayashi mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary Clin Cancer Res 15 2009 5404 5413
36. Y. Shi, A. Frankel, L.G. Radvanyi, L.Z. Penn, R.G. Miller, and G.B. Mills Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro Cancer Res 55 1995 1982 1988
37. N. Aissat, C. Le Tourneau, A. Ghoul, M. Serova, I. Bieche, and F. Lokiec Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines Cancer Chemother Pharmacol 62 2008 305 313
38. L.S. Faried, A. Faried, T. Kanuma, T. Nakazato, T. Tamura, and H. Kuwano Inhibition of the mammalian target of rapamycin (mTOR) by rapamycin increases chemosensitivity of CaSki cells to paclitaxel Eur J Cancer 42 2006 934 947
39. W.H. Mondesire, W. Jian, H. Zhang, J. Ensor, M.C. Hung, and G.B. Mills Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells Clin Cancer Res 10 2004 7031 7042
40. C.S. Chen, S.C. Weng, P.H. Tseng, and H.P. Lin Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes J Biol Chem 280 2005 38879 38887
41. R. Rao, P. Lee, W. Fiskus, Y. Yang, R. Joshi, and Y. Wang Co-treatment with heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17- demethoxygeldanamycin (DMAG) and vorinostat: a highly active combination against human mantle cell lymphoma (MCL) cells Cancer Biol Ther 8 2009 1273 1280
42. N. Kawamata, J. Chen, and H.P. Koeffler Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells Blood 110 2007 2667 2673
43. R. Axelsson, E. Martensson, and C. Alling Serum concentration and protein binding of thioridazine and its metabolites in patients with chronic alcoholism Eur J Clin Pharmacol 23 1982 359 363
44. A. Hercbergs Thioridazine: a radiation enhancer in advanced cervical cancer? Lancet 2 1988 737
45. L.K. Csatary Chlorpromazines and cancer Lancet 2 1972 338 339